Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States.
Steinmaus-C; Bates-MN; Yuan-Y; Kalman-D; Atallah-R; Rey-OA; Biggs-ML; Hopenhayn-C; Moore-LE; Hoang-BK; Smith-AH
J Occup Environ Med 2006 May; 48(5):478-488
OBJECTIVE: We sought to assess whether the metabolism of arsenic impacts a person's susceptibility to bladder cancer. METHODS: Urinary methylation products were measured in subjects from Argentina (114 cases and 114 controls) and the United States (23 cases and 49 controls). RESULTS: In Argentina, the adjusted odds ratio (OR) for subjects with a high proportion of ingested arsenic excreted as monomethylarsonate (%MMA) was 2.17 (95% confidence interval [CI] = 1.02-4.63) in smokers and 0.48 (95% CI = 0.17-1.33) in nonsmokers. In the United States, the adjusted ORs for high %MMA in subjects with arsenic intakes less than and greater than 100 microg/d were 1.20 (95% CI = 0.27-5.38) and 2.70 (95% CI = 0.39-18.6). CONCLUSIONS: Overall, these results are consistent with data from Taiwan suggesting that some individuals who excrete a higher proportion of ingested arsenic as MMA are more susceptible to arsenic-related cancer.
Biological-effects; Chemical-deposition; Chemical-hypersensitivity; Chemical-properties; Demographic-characteristics; Dietary-effects; Drinking-water; Exposure-assessment; Exposure-levels; Exposure-methods; Medical-monitoring; Physiological-effects; Physiological-measurements; Physiological-response; Risk-analysis; Smoking; Statistical-analysis; Urine-chemistry
Allan H. Smith, Arsenic Health Effects Research Program, School of Public Health, 140 Warren Hall, University of California, Berkeley, CA 94720-7360
Journal of Occupational and Environmental Medicine
University of California, Berkeley